secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nabriva Therapeutics plc (—)
CIK:        0001641640
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001104659-23-085605
Event type: m_and_a
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 1.02, 2.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nabriva sells lefamulin China rights to Sumitomo Pharma for $15M; directors resign, company winds down
--------------------------------------------------------------------------------

- Sumitomo Pharma pays $15M upfront: $10.4M to settle CMO obligations, $1.8M held back for indemnification.
- All four directors (Colin Broom, Carrie Bourdow, Lisa Dalton, Mark Corrigan) resigned immediately after closing.
- Post-closing operations limited to bridge support obligations, exploring sale of remaining assets, and wind-down.
- Bridge period through March 2024 (extendable to Sep 2024) with $2M pre-funded expense reimbursement from Sumitomo.
- XENLETA and CONTEPO are remaining assets; no guidance on shareholder recovery in wind-down process.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641640/000110465923085605/0001104659-23-085605-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641640/000110465923085605/tm2322342d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-085605

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer